From the Second Department of Internal Medicine, Osaka City University
Medical School, Osaka 545, Japan.
Correspondence to Atsushi Shioi, MD, Second Department of Internal Medicine, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, Osaka 545, Japan. E-mail as{at}msic.med.osaka-cu.ac.jp
Background—A significant
association between vascular calcification and osteoporosis has been
noted, suggesting that calcium homeostasis is important in vascular
calcification as well as in osteoporosis. Moreover, results of our
previous studies suggest that calcium-regulating hormones such as
parathyroid hormone–related peptide (PTHrP) may modulate vascular
calcification. Therefore, we hypothesized that 1
Methods and Results—We investigated the effect of
1,25(OH)2D3 on in vitro calcification by bovine
vascular smooth muscle cells (BVSMCs).
1,25(OH)2D3 dose dependently increased BVSMC
calcification and alkaline phosphatase activity.
1,25(OH)2D3 also decreased secretion of PTHrP
by BVSMCs in a dose-dependent manner and depressed its gene expression.
Furthermore, exogenous PTHrP (fragment 1-34) antagonized the
stimulatory effect of 1,25(OH)2D3 on BVSMCs.
Finally, 1,25(OH)2D3 dose dependently increased
the expression of the osteopontin gene, one of the bone matrix proteins
in BVSMCs, contributing to its stimulatory action on BVSMC
calcification.
Conclusions—These data suggest that
1,25(OH)2D3 exerts a stimulatory effect on
vascular calcification through direct inhibition of the expression of
PTHrP in BVSMCs as an endogenous
inhibitor of vascular calcification. Moreover, the
stimulatory effects of 1,25(OH)2D3 on alkaline
phosphatase activity and osteopontin expression may contribute to its
promoting action in vascular calcification.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
1,25-Dihydroxyvitamin D3 Increases In Vitro Vascular Calcification by Modulating Secretion of Endogenous Parathyroid Hormone–Related Peptide
,25-dihydroxyvitamin
D3 [1,25(OH)2D3] may have a
direct impact on the calcium-regulating system of vascular smooth
muscle cells, resulting in deposition of calcium in vascular
wall.
Key Words: calcification • vitamin D • muscle, smooth • peptides • osteoporosis
This article has been cited by other articles:
 |
|
 |
|
  M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Hsu, Y. Tintut, and L. L. Demer Vitamin D and Osteogenic Differentiation in the Artery Wall Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1542 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mathew, R. J. Lund, L. R. Chaudhary, T. Geurs, and K. A. Hruska Vitamin D Receptor Activators Can Protect against Vascular Calcification J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1509 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shroff, M. Egerton, M. Bridel, V. Shah, A. E. Donald, T. J. Cole, M. P. Hiorns, J. E. Deanfield, and L. Rees A Bimodal Association of Vitamin D Levels and Vascular Disease in Children on Dialysis J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Morrisett and K. C. Vickers Vascular Calcification in Homozygote Familial Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 606 - 607. [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. M. de Francisco and F. Carrera A New Paradigm for the Treatment of Secondary Hyperparathyroidism NDT Plus, January 1, 2008; 1(suppl_1): i24 - i28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Shroff, A. E. Donald, M. P. Hiorns, A. Watson, S. Feather, D. Milford, E. A. Ellins, C. Storry, D. Ridout, J. Deanfield, et al. Mineral Metabolism and Vascular Damage in Children on Dialysis J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2996 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wu-Wong, M. Nakane, J. Ma, X. Ruan, and P. E. Kroeger Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1592 - F1604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Orita, H. Yamamoto, N. Kohno, M. Sugihara, H. Honda, S. Kawamata, S. Mito, N. N. Soe, and M. Yoshizumi Role of Osteoprotegerin in Arterial Calcification: Development of New Animal Model Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2058 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Stubbs, S. Liu, W. Tang, J. Zhou, Y. Wang, X. Yao, and L. D. Quarles Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2116 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nikolov, N. Joki, T. Drueke, and Z. Massy Beyond phosphate--role of uraemic toxins in cardiovascular calcification Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3354 - 3357. [Full Text] [PDF]
|
|
|
|
|
|
A. L.M. de Francisco, C. Pinera, R. Palomar, and M. Arias Impact of Treatment with Calcimimetics on Hyperparathyroidism and Vascular Mineralization J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S281 - S285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Johnson, J. A. Leopold, and J. Loscalzo Vascular Calcification: Pathobiological Mechanisms and Clinical Implications Circ. Res., November 10, 2006; 99(10): 1044 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Briese, S. Wiesner, J. C. Will, A. Lembcke, B. Opgen-Rhein, R. Nissel, K.-D. Wernecke, J. Andreae, D. Haffner, and U. Querfeld Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease--impact of calcium and vitamin D therapy Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wu-Wong, W. Noonan, J. Ma, D. Dixon, M. Nakane, A. L. Bolin, K. A. Koch, S. Postl, S. J. Morgan, and G. A. Reinhart Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ketteler, G. Schlieper, and J. Floege Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon Hypertension, June 1, 2006; 47(6): 1027 - 1034. [Full Text] [PDF]
|
|
|
|
|
|
I. Lopez, E. Aguilera-Tejero, F. J. Mendoza, Y. Almaden, J. Perez, D. Martin, and M. Rodriguez Calcimimetic R-568 Decreases Extraosseous Calcifications in Uremic Rats Treated with Calcitriol J. Am. Soc. Nephrol., March 1, 2006; 17(3): 795 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Qunibi Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., November 1, 2005; 16(11_suppl_2): S95 - S102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Henley, M. Colloton, R. C. Cattley, E. Shatzen, D. A. Towler, D. Lacey, and D. Martin 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar(R)/Mimpara(R)) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Simmons, G. R. Grant, E. Manduchi, and P. F. Davies Spatial Heterogeneity of Endothelial Phenotypes Correlates With Side-Specific Vulnerability to Calcification in Normal Porcine Aortic Valves Circ. Res., April 15, 2005; 96(7): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Bachschmid and B. van der Loo A New "Sunshine" in the Vasculature? Circulation, April 5, 2005; 111(13): 1571 - 1573. [Full Text] [PDF]
|
|
|
|
|
|
D. Somjen, Y. Weisman, F. Kohen, B. Gayer, R. Limor, O. Sharon, N. Jaccard, E. Knoll, and N. Stern 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Is Expressed in Human Vascular Smooth Muscle Cells and Is Upregulated by Parathyroid Hormone and Estrogenic Compounds Circulation, April 5, 2005; 111(13): 1666 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rodriguez, E. Nemeth, and D. Martin The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism Am J Physiol Renal Physiol, February 1, 2005; 288(2): F253 - F264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Norman and J.T. Powell Vitamin D, Shedding Light on the Development of Disease in Peripheral Arteries Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Giachelli Vascular Calcification Mechanisms J. Am. Soc. Nephrol., December 1, 2004; 15(12): 2959 - 2964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Moe and N. X. Chen Pathophysiology of Vascular Calcification in Chronic Kidney Disease Circ. Res., September 17, 2004; 95(6): 560 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vattikuti and D. A. Towler Osteogenic regulation of vascular calcification: an early perspective Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E686 - E696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shoji, K. Shinohara, E. Kimoto, M. Emoto, H. Tahara, H. Koyama, M. Inaba, S. Fukumoto, E. Ishimura, T. Miki, et al. Lower risk for cardiovascular mortality in oral 1{alpha}-hydroxy vitamin D3 users in a haemodialysis population Nephrol. Dial. Transplant., January 1, 2004; 19(1): 179 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Shao, S.-L. Cheng, N. Charlton-Kachigian, A. P. Loewy, and D. A. Towler Teriparatide (Human Parathyroid Hormone (1-34)) Inhibits Osteogenic Vascular Calcification in Diabetic Low Density Lipoprotein Receptor-deficient Mice J. Biol. Chem., December 12, 2003; 278(50): 50195 - 50202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hirata, K. Katsumata, K. Endo, N. Fukushima, H. Ohkawa, and M. Fukagawa In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3 Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1770 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L Demer Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids Int. J. Epidemiol., August 1, 2002; 31(4): 737 - 741. [Full Text] [PDF]
|
|
|
|
|
|
A. Shioi, M. Katagi, Y. Okuno, K. Mori, S. Jono, H. Koyama, and Y. Nishizawa Induction of Bone-Type Alkaline Phosphatase in Human Vascular Smooth Muscle Cells: Roles of Tumor Necrosis Factor-{alpha} and Oncostatin M Derived From Macrophages Circ. Res., July 12, 2002; 91(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Rebsamen, J. Sun, A. W. Norman, and J. K. Liao 1{alpha},25-Dihydroxyvitamin D3 Induces Vascular Smooth Muscle Cell Migration via Activation of Phosphatidylinositol 3-Kinase Circ. Res., July 12, 2002; 91(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. DOHERTY, H. UZUI, L. A. FITZPATRICK, P. V. TRIPATHI, C. R. DUNSTAN, K. ASOTRA, and T. B. RAJAVASHISTH Rationale for the role of osteoclast-like cells in arterial calcification FASEB J, April 1, 2002; 16(6): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Price, S. A. Faus, and M. K. Williamson Bisphosphonates Alendronate and Ibandronate Inhibit Artery Calcification at Doses Comparable to Those That Inhibit Bone Resorption Arterioscler. Thromb. Vasc. Biol., May 1, 2001; 21(5): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Goldstein, S. Jono, Y. Nishizawa, A. Shioi, and H. Morii Long-Term Therapy for Postmenopausal Osteoporosis: Stronger Bones but Weaker Arteries? • Response Circulation, July 27, 1999; 100 (4): 446 - 449. [Full Text] [PDF]
|
|
|
|
|
|
S. Jono, C. Peinado, and C. M. Giachelli Phosphorylation of Osteopontin Is Required for Inhibition of Vascular Smooth Muscle Cell Calcification J. Biol. Chem., June 23, 2000; 275(26): 20197 - 20203. [Abstract] [Full Text] [PDF]
|
|